{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-086740","form_type":"8-K","ticker":"ELUT","cik":"0001708527","company_name":"ELUTIA INC.","filed_at":"2024-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.199210+00:00","generated_at":"2026-05-31T11:49:25.580415+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Elutia Q2 net loss widens to $28.2M on warrant revaluation; EluPro launch underway","bullets":["Net loss $28.2M vs $10.6M YoY; includes $18.3M non-cash warrant revaluation charge.","Total net sales flat at $6.3M; CanGaroo +19% to $2.6M, SimpliDerm +7% to $2.6M.","FDA clearance for EluPro received; manufacturing commenced; commercial team expanding.","Cash $18.2M at quarter end; $13.8M additional from post-quarter warrant exercises.","Adjusted EBITDA loss improved to $2.9M from $3.4M in prior-year quarter."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-086740","json":"https://secwatch.observer/filing/0001104659-24-086740.json","markdown":"https://secwatch.observer/filing/0001104659-24-086740.md","text":"https://secwatch.observer/filing/0001104659-24-086740.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708527/000110465924086740/0001104659-24-086740-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708527/000110465924086740/tm2421059d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:49:25.580415+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}